DMP 266 non-nucleoside blocker of reverse transcriptase data

Data from an ongoing Phase II trial of DuPont Merck's DMP 266 combined with Merck's Crixivan show that 80 percent of 21

Read the full 222 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE